Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Asset Writedowns and Impairment (2020 - 2025)

PROCEPT BioRobotics (PRCT) has disclosed Asset Writedowns and Impairment for 6 consecutive years, with -$861000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Asset Writedowns and Impairment fell 324.22% to -$861000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $565000.0, a 32.74% decrease, with the full-year FY2025 number at $565000.0, down 32.74% from a year prior.
  • Asset Writedowns and Impairment was -$861000.0 for Q4 2025 at PROCEPT BioRobotics, down from $526000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $600000.0 in Q2 2025 to a low of -$995000.0 in Q4 2023.
  • A 5-year average of $121538.5 and a median of $228000.0 in 2023 define the central range for Asset Writedowns and Impairment.
  • Biggest YoY gain for Asset Writedowns and Impairment was 567.82% in 2023; the steepest drop was 3880.0% in 2023.
  • PROCEPT BioRobotics' Asset Writedowns and Impairment stood at $113000.0 in 2021, then crashed by 122.12% to -$25000.0 in 2022, then plummeted by 3880.0% to -$995000.0 in 2023, then soared by 138.59% to $384000.0 in 2024, then crashed by 324.22% to -$861000.0 in 2025.
  • Per Business Quant, the three most recent readings for PRCT's Asset Writedowns and Impairment are -$861000.0 (Q4 2025), $526000.0 (Q3 2025), and $600000.0 (Q2 2025).